Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
Oct 15, 2018 • 9:00 AM EDT
Ligand to Report Third Quarter 2018 Results on November 8th
Oct 10, 2018 • 9:00 AM EDT
Ligand Announces the Close of its Acquisition of Vernalis
Aug 29, 2018 • 9:00 AM EDT
Ligand to Participate in H.C. Wainwright 20th Annual Global Investment Conference
Sep 5, 2018 • 12:30pm EDT
St. Regis Hotel, New York, NY
See all events
Aug 6, 2018 • 4:30pm EDT
Jun 19, 2018 • 8:30am PDT
3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA 92121
Nov 8, 2018 • 9:00am EDT
Corvus Pharmaceuticals to present data on lead programs at the European Society for Medical Oncology (ESMO) 2018 an… https://t.co/QC5fy26t0H
Corvus Pharmaceuticals announces publication of preclinical results highlighting antitumor activity of CPI-444 in m… https://t.co/lHGPmbKRwE
Sermonix Launches Phase 2 trial to evaluate investigational oral Lasofoxifene as a targeted precision treatment for… https://t.co/L3r77f901G